APOE and metabolic dysfunction-associated steatotic liver disease: The APOE e3 allele (Sazci et al., 2008) is also significantly more prevalent in biopsy-proven NASH patients compared to controls, whereas the APOE e2 allele appears protective against NAFLD (Demirag et al., 2007).